GB8728294D0 — Treatment compositions
Assigned to Reckitt Benckiser Healthcare UK Ltd · Expires 1988-01-06 · 38y expired
What this patent protects
A pharmaceutical composition in sublingual unit dosage form for maintenance treatment of opiate addicts comprising from 2 to 8mg buprenorphine and an amount of naltrexone sufficient to substantially attenuate the euphorigenic effect of the buprenorphine when injected and to provi…
USPTO Abstract
A pharmaceutical composition in sublingual unit dosage form for maintenance treatment of opiate addicts comprising from 2 to 8mg buprenorphine and an amount of naltrexone sufficient to substantially attenuate the euphorigenic effect of the buprenorphine when injected and to provide greater opiate blocking effect than that of naltrexone alone.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.